Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 1, 2017. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a single share acquisition transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares following the exercise of options under the Company's ShareSave Plan.
- Transaction Date: December 1, 2017.
- Price per Share: £11.31.
- Volume: 238 shares.
- Location: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine exercise of employee stock options by a Person Discharging Managerial Responsibilities (PDMR).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Mr. S. Dingemans, Chief Financial Officer.
- Option Grant Date: The shares were acquired from options originally granted on October 29, 2014.
- Transaction Scale: The volume of 238 shares represents a negligible impact on total share capital.
- Regulatory Context: This filing satisfies reporting requirements under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.